EUCAST Technical note on Amphotericin B

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages

  Lass Florl C ^a   Arendrup, M C ^b   Rodriguez Tudela, J L ^c   Cuenca Estrella, M ^c   Donnelly, P ^d   Hope, W ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b STATENS SERUM INSTITUT   (Denmark)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amphotericin B; Breakpoints; EUCAST technical note; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG FORMULATION; DRUG RESEARCH; DRUG TREATMENT FAILURE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 81255127375     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03644.x     Document Type: Note

References (15)

1. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericn B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-833.
2. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-840.
3. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
4. Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15mg/kg), weekly dose (7.5mg/kg), or daily dose (1mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother 2009; 53: 3664-3674.
5. Adedoyin A, Bernardo JF, Swenson CE et al. Pharmacokinetic profile of ABELECET (amphotericin B lipid complex injection): combined experiences from phase I and phase II studies. Antimicrob Agents Chemother 1997; 41: 2201-2208.
6. Adedoyin A, Swenson CE, Bolcsak LE et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelecet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000; 44: 2900-2902.
7. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. The population pharmacokinetics of amphotericn B colloidal dispersion in patients receiving bone marrow transplants. Chemotherapy 1999; 45 (Suppl. 1): 48-53.
8. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericn B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
9. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163.
10. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
11. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
12. Kuse ER, Chetchotisakd P, Da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369: 1519-1527.
13. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-826.
14. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511-520.
15. Noskin G, Pietrelli L, Gurwith M, Bowden R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999; 23: 697-703.